EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Rationalizing a prospective coupling effect of cannabinoids with the current pharmacotherapy for melanoma treatment

Ava Bachari iD, Nazim Nassar iD, Ellen Schanknecht iD, Srinivasareddy Telukutla iD, Terrence Jerald Piva iD, Nitin Mantri iD

WIREs Mechanisms of Disease · 2024

DOI: 10.1002/wsbm.1633 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift WIREs Mechanisms of Disease, 2024. Verfasst von Ava Bachari und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Pangenomics Lab, School of Science, RMIT University, Bundoora, Victoria, Australia. Hauptthemen laut MEDLINE: Cannabinoids, Melanoma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 289 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Melanoma is one of the leading fatal forms of cancer, yet from a treatment perspective, we have minimal control over its reoccurrence and resistance to current pharmacotherapies. The endocannabinoid system (ECS) has recently been accepted as a multifaceted homeostatic regulator, influencing various physiological processes across different biological compartments, including the skin. This review presents an overview of the pathophysiology of melanoma, current pharmacotherapy used for treatment, and the challenges associated with the different pharmacological approaches. Furthermore, it highlights the utility of cannabinoids as an additive remedy for melanoma by restoring the balance between downregulated immunomodulatory pathways and elevated inflammatory cytokines during chronic skin conditions as one of the suggested critical approaches in treating this immunogenic tumor. This article is categorized under: Cancer > Molecular and Cellular Physiology

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabinoidsMelanomaHumansProspective StudiesEndocannabinoidsSkin

Stichwörter der Autor:innen

cancer treatmentcannabinoidsmechanismsmelanomapharmacotherapy

Substanzen

CannabinoidsEndocannabinoids

Autor:innen und Institutionen

  • The Pangenomics Lab, School of Science, RMIT University, Bundoora, Victoria, Australia.
  • School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia.
  • The UWA Institute of Agriculture, The University of Western Australia, Perth, Western Australia, Australia.

ORCID-Profile: Ava Bachari, Nazim Nassar, Ellen Schanknecht, Srinivasareddy Telukutla, Terrence Jerald Piva, Nitin Mantri

Zitieren

APA

Bachari, A., Nassar, N., Schanknecht, E., Telukutla, S., Piva, T. J., & Mantri, N. (2024). Rationalizing a prospective coupling effect of cannabinoids with the current pharmacotherapy for melanoma treatment. WIREs Mechanisms of Disease. https://doi.org/10.1002/wsbm.1633

Vancouver

Bachari A, Nassar N, Schanknecht E, Telukutla S, Piva TJ, Mantri N. Rationalizing a prospective coupling effect of cannabinoids with the current pharmacotherapy for melanoma treatment. WIREs Mechanisms of Disease. 2024. doi:10.1002/wsbm.1633

BibTeX
@article{Bachari2024,
  author = {Bachari, Ava and Nassar, Nazim and Schanknecht, Ellen and Telukutla, Srinivasareddy and Piva, Terrence Jerald and Mantri, Nitin},
  title = {Rationalizing a prospective coupling effect of cannabinoids with the current pharmacotherapy for melanoma treatment},
  journal = {WIREs Mechanisms of Disease},
  year = {2024},
  doi = {10.1002/wsbm.1633}
}
Kostenlos starten →